Takeda Pharmaceutical Company Limited

Takeda Chemical Industries, Inc.

Tomoyasu Ishikawa

Masaki Seto

Takahiko Taniguchi

Shohei Hashiguchi

Yuji Iizawa

Hiroshi Banno

The present invention relates to a compound represented by the formula: wherein W is C(R) or N, each A is an optionally substituted aryl group or a heteroaryl group, Xis &#x2014;NR&#x2014;Y&#x2014;, &#x2014;O&#x2014;, &#x2014;S&#x2014;, &#x2014;SO&#x2014;, &#x2014;SO&#x2014; or &#x2014;CHR&#x2014; wherein Ris a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or Ris optionally bonded to A to form an optionally substituted ring structure, Ris a hydrogen atom or an optionally substituted group bonded via a carbon atom, a nitrogen atom or an oxygen atom, Ris a hydrogen atom or optionally substituted group bonded via a carbon atom or a sulfur atom, or Rand R, or Rand Rare optionally bonded to form an optionally substituted ring structure, or a salt thereof, and a tyrosine kinase inhibitor or an agent for the prophylaxis or treatment of cancer, which contains this compound or a prodrug thereof.

Bi- and tricyclic fused pyrimidines as tyrosine kinase inhibitors

Fused heterocyclic compound

A cephem compound (particularly its crystal) represented by the formula [I], wherein X is CHCOOH, CHCHCOOH or CHCN, and n is 0 to 5, is useful as an antibacterial agent (particularly anti-MRSA agent) and shows superior quality such as high solid stability, possible long-term stable preservation and the like. 

Phosphonocephem compound

A cephem compound (particularly its crystal) represented by the formula [I], wherein X is CHCOOH, CHCHCOOH or CHCN, and n is 0 to 5, is useful as an antibacterial agent (particularly anti-MRSA agent) and shows superior quality such as high solid stability, possible long-term stable preservation and the like.

Phosphonocephem derivatives, process for the preparation of the same, and use thereof

Growing community of inventors

Shiga, Japan

Tomoyasu Ishikawa